https://pepsreview.com/articles/new-zealand-needle-exchange-peptide-kits-2300-six-weeks PepsReview en 2026-11-05 peptide injecting kits, needle exchange New Zealand, unapproved peptides, Medsafe peptide warning, harm reduction, BPC-157, retatrutide, peptide regulation https://pepsreview.com/articles/glp1-vs-metformin-prediabetes-256000-patient-study PepsReview en 2026-11-05 GLP-1 prediabetes, metformin comparison, type 2 diabetes prevention, semaglutide, tirzepatide, AHA Scientific Sessions 2026, observational study https://pepsreview.com/articles/generic-semaglutide-india-exports-torrent-brazil PepsReview en 2026-11-05 generic semaglutide, Torrent Pharmaceuticals, Brazil semaglutide patent, India generics, GLP-1 supply chain, Novo Nordisk patent expiry https://pepsreview.com/articles/celltrion-four-target-obesity-drug-mouse-study PepsReview en 2026-11-04 Celltrion CT-G32, quadruple agonist, obesity drug pipeline, GLP-1, retatrutide, preclinical data, IND filing, lean mass preservation https://pepsreview.com/articles/novo-aasld-2026-semaglutide-efruxifermin-mash-liver-data PepsReview en 2026-11-04 semaglutide MASH, AASLD 2026, efruxifermin, MASH liver disease, GLP-1 liver data, ESSENCE trial, resmetirom https://pepsreview.com/articles/tga-approves-first-oral-glp1-weight-loss-tablet-australia PepsReview en 2026-11-03 TGA Wegovy tablet, oral semaglutide Australia, GLP-1 tablet approval, Wegovy pill, unapproved peptides, peptide testing, GLP-1 regulation https://pepsreview.com/articles/fda-approves-once-weekly-insulin-children-type-2-diabetes PepsReview en 2026-11-03 insulin icodec, once-weekly insulin, pediatric type 2 diabetes, FDA approval, Awiqli, peptide therapeutics, GLP-1 https://pepsreview.com/articles/nine-in-ten-eligible-teens-received-neither-glp1-nor-surgery PepsReview en 2026-11-03 adolescent obesity, GLP-1 access, bariatric surgery adolescents, JAMA Pediatrics, semaglutide adolescents, pediatric obesity treatment, insurance coverage GLP-1